Those were quick gains. Maybe we've attracted the interest of a few optimistic longs?
This stock is trading too low. Not only the drug potential, but management has been great at managing the spend. I expect to see buyout rumors with a target price north of $30 after Q1 2014.
I have not known JF to lose. ABI tried to squeeze him when ILMN was a $50M company. Let's put this nonsense to rest and focus on saving lives (and profits of course).
GERN was down to .91 and look at what it hit today. Let's hope SQNM does the same from here.
It's unfortunate that SQNM has traded this low for this long. Too many day traders with low averages, flipping shares for an easy 5%+. An 11% spike is now only $2.87 and it doesn't even hold!!! Those with averages in the low $3's are screwed.
You shouldn't feel confident. The company has losses that total close to $1B and is only valued at $300M with plans to sell-off a big chunk. The short interest is incredibly high and SQNM continues to battle operational issues and lawsuits that bleed money. This is a lottery ticket! If it hits, it will payoff big. I'm here because I believe the risk is worth the reward. (It's clear the majority does not.) However, with all of the current challenges, it would be foolish to think that something great will happen in the short-term. We need a catalyst that drives demand and presses the shorts to cover. It's no guarantee that reaching profitability will do that. In the meantime, the negative forces out there will stop at nothing to crush this company. Here's to a good fight!
ACAD is set to go much higher. Very similar to JAZZ run from $5 to $90. Now trading at 7x sales. ACAD expected to reach a $2B market. Will get very exciting when the product hits market.
I'm not invested in the company but gives an appreciation for what can happen with SQNM.
Everything seems to be missing the point. Motley Fool articles with poor evaluation, posts on trial or injunction, power of the shorts, worth of GA business and company's overall outlook.
The GA business could sell at a major premium to the right partner. Someone who has a greater customer channel who could easily integrate SQNM's offerings (t larger scale and lower cost). Products and consumables are superior to many others on the market. There is value greater than the 5 x $40M, basic ROI analysis.
With a cash infusion greater than $200M, SQNM will have the funds it needs to cover the court case, another year of expenses and drive towards profitability. With cash on hand and a streamlined focus on diagnostics, a booming area with higher margins, the company will be poised for significant appreciation.
Resolving the collection issues and changes to revenue recognition will be the other catalysts that promote healthy finances on paper.
Credit to the shorts, why? The short interest has been high for many years. Who's to assume that most aren't owned by institutions as a hedge on long positions for a stock that trades under $5? Lastly, if you are an independent short who is out to squash the company, then you need your head examined for bashing a company full of MDs and PhDs who are out to protect and benefit mankind. If it needs to be done, then be discrete about it. Those aren't gains that I would ever take pride in.
I believe that exciting times are ahead and milestones of improvement will be apparent within the next two quarters. At this level, I'm hanging in and riding it out as a long-term investment as opposed to a trade. The company may be down but it is not out! Good luck.
If management pulls this off correctly, the upside could be huge. Sell-off the piece with lagging growth and margin while investing in the opposite growth areas. Coupled with a little luck (or should I say fairness) in court and SQNM will be a market leader in diagnostic services. There are many variables at play. However, getting in at a 5 year low could be very rewarding. Especially while the short interest tops 30%. Once the coding and billing issues are resolved, shorts will lose another critical scapegoat.
The only thing that's up is the demand. Now 93% institutional interest. New entities cannot get enough shares without driving the price up. Baker Bros will continue to make a fortune. Let's hope that there is not a buyout looming and let ACAD reach a $10B market cap on its own. I'm not selling until at least then.
A little thing called proteomics would take an additional 15 years to sort out, as having the genes does not guarantee anything. Keep pumping though...